Endocrine therapy and thyroid function in early luminal breast cancer: a controlled longitudinal retrospective analysis - Takeaways - MDSpire

Endocrine therapy and thyroid function in early luminal breast cancer: a controlled longitudinal retrospective analysis

  • By

  • Zengwei Li

  • Tingfei Song

  • Yu Zhang

  • Yonghui Wang

  • Hui Sun

  • June 18, 2026

  • 0 min

Share

  • 1

    Adjuvant endocrine therapy for early luminal breast cancer significantly alters thyroid function over three years.

  • 2

    Patients receiving endocrine therapy showed increased TSH and decreased FT3 and FT4 compared to benign breast disease controls.

  • 3

    The study found significant group-by-time interactions for TSH, FT3, and FT4, indicating distinct thyroid function changes.

  • 4

    Subgroup analysis revealed a greater decline in FT4 with tamoxifen compared to aromatase inhibitors, though not statistically significant for TSH or FT3.

  • 5

    The small sample size and collinearity of treatment type and menopausal status limit conclusions about the differential effects of tamoxifen and AIs.

Original Source(s)

Endocrine therapy and thyroid function in early luminal breast cancer: a controlled longitudinal retrospective analysis

  • by Zengwei Li, Tingfei Song, Yu Zhang, Yonghui Wang, Hui Sun

  • June 18, 2026

Related Content

Enhanced differentiation of breast lesions through integration of microvascular flow imaging and machine learning algorithms

Trastuzumab emtansine versus trastuzumab plus pertuzumab for HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world study

Machine learning-driven identification and immunohistochemical validation of an integrated immune-inflammatory phenotype for disease-free survival stratification in breast cancer